Márcia Nery
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Márcia Nery has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Marcos Tadashi Kakitani Toyoshima
Endocrine Oncology Service. Instituto do Cancer do Estado de São Paulo Octávio Frias de Oliveira. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Sao Paulo, Brazil; Laboratório de Carboidratos e Radioimunoensaio (LIM18), Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil
6 shared publications - Alexandre Barbosa Câmara de Souza
Department of Endocrinology and Metabolism, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
3 shared publications - Alina Coutinho Rodrigues Feitosa
Faculty of Medicine, Zarns, Brazil
3 shared publications - Maria Lúcia Corrêa-Giannella
Laboratório de Carboidratos e Radioimunoensaio (LIM18) do Hospital das Clínicas (HCFMUSP) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
3 shared publications - Marilia Brito Gomes
Department of Internal Medicine, Diabetes Unit, State University of Rio de Janeiro, Rio de Janeiro, Brazil
3 shared publications - Adriana Costa Forti
Universidade Federal do Ceará, Brazil
2 shared publications
Latest Publications
- Open Access
- 10 May 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-5
A decade of InsulinAPP: validation using COSMIN and clinical advancements since its initial publication
This correspondence marks the 10-year milestone of InsulinAPP, a Brazilian-developed electronic glycemic management system (eGMS) designed to support inpatient insulin therapy. Initially published in 2015, InsulinAPP was developed to assist non-specialist physicians in applying evidence-based insulin protocols in hospital settings. Over the past decade, it has evolved into a validated clinical decision-support tool with demonstrated impact across multiple care contexts. In this manuscript, we present a structured overview of its validation using the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) framework, assessing five core domains: cross-cultural adaptation, content validity, criterion validity, reliability, and construct validity. Usability testing showed high acceptance (mean Likert score 4.8/5), and expert consensus on content validity was strong (Content Validity Index = 0.95). The tool also demonstrated high reproducibility (intraclass correlation coefficient = 0.98), and in a randomized trial, glycemic control with InsulinAPP was comparable to endocrinologist-led care, with low hypoglycemia rates. Compared to other eGMS solutions, InsulinAPP stands out for its simplicity, independence from electronic health record integration, and adaptability to low-resource environments. Its protocol anticipated updates later adopted by the Endocrine Society and the Brazilian Diabetes Society, particularly regarding stratified insulinization for patients with mild-to-moderate hyperglycemia. Together, these findings confirm InsulinAPP’s scientific soundness, safety, and real-world applicability. Broader implementation and multicenter studies are warranted to further explore its impact in diverse healthcare systems and improve access to safe inpatient glycemic management.
- 10 May 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-5
Open AccessA decade of InsulinAPP: validation using COSMIN and clinical advancements since its initial publication
This correspondence marks the 10-year milestone of InsulinAPP, a Brazilian-developed electronic glycemic management system (eGMS) designed to support inpatient insulin therapy. Initially published in 2015, InsulinAPP was developed to assist non-specialist physicians in applying evidence-based insulin protocols in hospital settings. Over the past decade, it has evolved into a validated clinical decision-support tool with demonstrated impact across multiple care contexts. In this manuscript, we present a structured overview of its validation using the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) framework, assessing five core domains: cross-cultural adaptation, content validity, criterion validity, reliability, and construct validity. Usability testing showed high acceptance (mean Likert score 4.8/5), and expert consensus on content validity was strong (Content Validity Index = 0.95). The tool also demonstrated high reproducibility (intraclass correlation coefficient = 0.98), and in a randomized trial, glycemic control with InsulinAPP was comparable to endocrinologist-led care, with low hypoglycemia rates. Compared to other eGMS solutions, InsulinAPP stands out for its simplicity, independence from electronic health record integration, and adaptability to low-resource environments. Its protocol anticipated updates later adopted by the Endocrine Society and the Brazilian Diabetes Society, particularly regarding stratified insulinization for patients with mild-to-moderate hyperglycemia. Together, these findings confirm InsulinAPP’s scientific soundness, safety, and real-world applicability. Broader implementation and multicenter studies are warranted to further explore its impact in diverse healthcare systems and improve access to safe inpatient glycemic management.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Gene Expression in Urinary Sediment Cells as an Indicator of the Contribution of Plasma Lipids to Diabetic Kidney Disease
Background: In individuals with Type 1 diabetes mellitus (T1D) who maintain good glycemic control and are free of chronic complications, lipid profiles are generally within normal ranges. However, impaired renal function or albuminuria alters this profile, contributing to the progression of diabetic kidney disease (DKD). This study hypothesized that, in urinary sediment cells from T1D individuals ( n = 87), the mRNA expression of genes related to free fatty acid (FFA) uptake ( CD36 , FABP1 , SCL27A1 , SLC27A2 , and SLC27A4 , which encode FATP1 , FATP2 , and FATP4 , respectively), albumin uptake ( LRP2 and CUBN ), inflammation ( IL1B and IL18 ), and fibrosis ( TGFB1 ) would vary depending on the degree of renal function decline and of urinary albumin excretion (UAE) and correlate with each other and with plasma lipid concentrations. Results: CD36 expression was higher in urinary sediment cells of individuals with relevant renal function decline compared to those without relevant decline. CD36 , IL1B , TGFB1 , and SLC27A4 (at the limit of statistical significance) expressions were higher in individuals with UAE > 11 mg/g versus UAE ≤ 11 mg/g creatinine (cohort median value). CD36 expression positively correlated with IL1B ( r = 0.46) and TGFB1 ( r = 0.45) expressions, and LRP2 expression positively correlated with IL18 ( r = 0.44) and TGFB1 ( r = 0.30). Expression of SLC27A genes also correlated with inflammatory and profibrotic genes. Plasma FFA concentrations positively correlated with CD36 ( r = 0.27) and IL1B ( r = 0.30) expressions, while plasma triglyceride (TG) concentrations positively correlated with CD36 ( r = 0.22) and negatively correlated with FABP1 ( r = −0.28) expressions. Urinary sediment gene expression was modulated by statin ( IL18 ) and angiotensin II receptor blockers ( LRP2 , CUBN , and FABP1 ) use. Conclusions: The expression of lipid metabolism–related genes in urinary sediment cells, correlated with proinflammatory and profibrotic genes, as well as with plasma FFA and TG, and associated with clinical indicators of renal function, provides indirect evidence for the involvement of lipids in the pathogenesis of DKD.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Open AccessGene Expression in Urinary Sediment Cells as an Indicator of the Contribution of Plasma Lipids to Diabetic Kidney Disease
Background: In individuals with Type 1 diabetes mellitus (T1D) who maintain good glycemic control and are free of chronic complications, lipid profiles are generally within normal ranges. However, impaired renal function or albuminuria alters this profile, contributing to the progression of diabetic kidney disease (DKD). This study hypothesized that, in urinary sediment cells from T1D individuals ( n = 87), the mRNA expression of genes related to free fatty acid (FFA) uptake ( CD36 , FABP1 , SCL27A1 , SLC27A2 , and SLC27A4 , which encode FATP1 , FATP2 , and FATP4 , respectively), albumin uptake ( LRP2 and CUBN ), inflammation ( IL1B and IL18 ), and fibrosis ( TGFB1 ) would vary depending on the degree of renal function decline and of urinary albumin excretion (UAE) and correlate with each other and with plasma lipid concentrations. Results: CD36 expression was higher in urinary sediment cells of individuals with relevant renal function decline compared to those without relevant decline. CD36 , IL1B , TGFB1 , and SLC27A4 (at the limit of statistical significance) expressions were higher in individuals with UAE > 11 mg/g versus UAE ≤ 11 mg/g creatinine (cohort median value). CD36 expression positively correlated with IL1B ( r = 0.46) and TGFB1 ( r = 0.45) expressions, and LRP2 expression positively correlated with IL18 ( r = 0.44) and TGFB1 ( r = 0.30). Expression of SLC27A genes also correlated with inflammatory and profibrotic genes. Plasma FFA concentrations positively correlated with CD36 ( r = 0.27) and IL1B ( r = 0.30) expressions, while plasma triglyceride (TG) concentrations positively correlated with CD36 ( r = 0.22) and negatively correlated with FABP1 ( r = −0.28) expressions. Urinary sediment gene expression was modulated by statin ( IL18 ) and angiotensin II receptor blockers ( LRP2 , CUBN , and FABP1 ) use. Conclusions: The expression of lipid metabolism–related genes in urinary sediment cells, correlated with proinflammatory and profibrotic genes, as well as with plasma FFA and TG, and associated with clinical indicators of renal function, provides indirect evidence for the involvement of lipids in the pathogenesis of DKD.
- 3 August 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (2) , 308-316
Electronic Glycemic Management System Improved Glycemic Control and Reduced Complications in Patients With Diabetes Undergoing Coronary Artery Bypass Surgery: A Randomized Controlled Trial
Background: In-hospital hyperglycemia poses significant risks for patients with diabetes mellitus undergoing coronary artery bypass graft (CABG) surgery. Electronic glycemic management systems (eGMSs) like InsulinAPP offer promise in standardizing and improving glycemic control (GC) in these settings. This study evaluated the efficacy of the InsulinAPP protocol in optimizing GC and reducing adverse outcomes post-CABG. Methods: This prospective, randomized, open-label study was conducted with 100 adult type 2 diabetes mellitus (T2DM) patients post-CABG surgery, who were randomized into two groups: conventional care (gCONV) and eGMS protocol (gAPP). The gAPP used InsulinAPP for insulin therapy management, whereas the gCONV received standard clinical care. The primary outcome was a composite of hospital-acquired infections, renal function deterioration, and symptomatic atrial arrhythmia. Secondary outcomes included GC, hypoglycemia incidence, hospital stay length, and costs. Results: The gAPP achieved lower mean glucose levels (167.2 ± 42.5 mg/dL vs 188.7 ± 54.4 mg/dL; P = .040) and fewer patients-day with BG above 180 mg/dL (51.3% vs 74.8%, P = .011). The gAPP received an insulin regimen that included more prandial bolus and correction insulin (either bolus-correction or basal-bolus regimens) than the gCONV (90.3% vs 16.7%). The primary composite outcome occurred in 16% of gAPP patients compared with 58% in gCONV ( P < .010). Hypoglycemia incidence was lower in the gAPP (4% vs 16%, P = .046). The gAPP protocol also resulted in shorter hospital stays and reduced costs. Conclusions: The InsulinAPP protocol effectively optimizes GC and reduces adverse outcomes in T2DM patients’ post-CABG surgery, offering a cost-effective solution for inpatient diabetes management.
- 3 August 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (2) , 308-316
Electronic Glycemic Management System Improved Glycemic Control and Reduced Complications in Patients With Diabetes Undergoing Coronary Artery Bypass Surgery: A Randomized Controlled Trial
Background: In-hospital hyperglycemia poses significant risks for patients with diabetes mellitus undergoing coronary artery bypass graft (CABG) surgery. Electronic glycemic management systems (eGMSs) like InsulinAPP offer promise in standardizing and improving glycemic control (GC) in these settings. This study evaluated the efficacy of the InsulinAPP protocol in optimizing GC and reducing adverse outcomes post-CABG. Methods: This prospective, randomized, open-label study was conducted with 100 adult type 2 diabetes mellitus (T2DM) patients post-CABG surgery, who were randomized into two groups: conventional care (gCONV) and eGMS protocol (gAPP). The gAPP used InsulinAPP for insulin therapy management, whereas the gCONV received standard clinical care. The primary outcome was a composite of hospital-acquired infections, renal function deterioration, and symptomatic atrial arrhythmia. Secondary outcomes included GC, hypoglycemia incidence, hospital stay length, and costs. Results: The gAPP achieved lower mean glucose levels (167.2 ± 42.5 mg/dL vs 188.7 ± 54.4 mg/dL; P = .040) and fewer patients-day with BG above 180 mg/dL (51.3% vs 74.8%, P = .011). The gAPP received an insulin regimen that included more prandial bolus and correction insulin (either bolus-correction or basal-bolus regimens) than the gCONV (90.3% vs 16.7%). The primary composite outcome occurred in 16% of gAPP patients compared with 58% in gCONV ( P < .010). Hypoglycemia incidence was lower in the gAPP (4% vs 16%, P = .046). The gAPP protocol also resulted in shorter hospital stays and reduced costs. Conclusions: The InsulinAPP protocol effectively optimizes GC and reduces adverse outcomes in T2DM patients’ post-CABG surgery, offering a cost-effective solution for inpatient diabetes management.
- Open Access
- 3 October 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (6) , 784-791
Epidemiology and risk factors of hypoglycemia in subjects with type 1 diabetes in Brazil: a cross-sectional, multicenter study
Objective: The aim of this study was to investigate the factors associated with hypoglycemia and severe hypoglycemia (SH) in individuals with type 1 diabetes mellitus (T1D) in Brazil. Materials and methods: This multicenter, cross-sectional study was conducted between August 2011 and August 2014 across 10 Brazilian cities. The data were obtained from 1,760 individuals with T1D. Sociodemographic and clinical characteristics related to hypoglycemic events in the previous 4 weeks were evaluated. Results: Of 1,760 individuals evaluated, 1,319 (74.9%) reported [...] ABSTRACT Objective: The aim of this study was to investigate the factors associated with hypoglycemia and severe hypoglycemia (SH) in individuals with type 1 diabetes mellitus (T1D) in Brazil. Materials and methods: This multicenter, cross-sectional study was conducted between August 2011 and August 2014 across 10 Brazilian cities. The data were obtained from 1,760 individuals with T1D. Sociodemographic and clinical characteristics related to hypoglycemic events in the previous 4 weeks were evaluated. Results: Of 1,760 individuals evaluated, 1,319 (74.9%) reported
- 3 October 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (6) , 784-791
Open AccessEpidemiology and risk factors of hypoglycemia in subjects with type 1 diabetes in Brazil: a cross-sectional, multicenter study
Objective: The aim of this study was to investigate the factors associated with hypoglycemia and severe hypoglycemia (SH) in individuals with type 1 diabetes mellitus (T1D) in Brazil. Materials and methods: This multicenter, cross-sectional study was conducted between August 2011 and August 2014 across 10 Brazilian cities. The data were obtained from 1,760 individuals with T1D. Sociodemographic and clinical characteristics related to hypoglycemic events in the previous 4 weeks were evaluated. Results: Of 1,760 individuals evaluated, 1,319 (74.9%) reported [...] ABSTRACT Objective: The aim of this study was to investigate the factors associated with hypoglycemia and severe hypoglycemia (SH) in individuals with type 1 diabetes mellitus (T1D) in Brazil. Materials and methods: This multicenter, cross-sectional study was conducted between August 2011 and August 2014 across 10 Brazilian cities. The data were obtained from 1,760 individuals with T1D. Sociodemographic and clinical characteristics related to hypoglycemic events in the previous 4 weeks were evaluated. Results: Of 1,760 individuals evaluated, 1,319 (74.9%) reported
- 19 September 2022
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 21 (2) , 1661-1667
Diet consistency modification improves postprandial glycemic and gastroparesis symptoms
Diabetic gastroparesis (DGP) is an autonomic neuropathy resulting from long-standing poorly controlled diabetes, and it is also linked to fluctuations in glycemic control due to variability on nutrient absorption. Considering the scarcity of information, the aim of this study was to identify the impact of modifications on diet consistency on post-prandial glucose variability using a continuous glucose monitoring (CGM) and its effect on the perception and severity of gastrointestinal symptoms. This proof-of-concept study was carried out in a cross-sectional cohort of six individuals with type 1 diabetes mellitus with confirmed diagnosis of DGP. Two types of diet were used to evaluate glycemic control and DGP symptoms, general consistency standard meal (SD) and modified consistency test diet (MD), associated with an application of rapid acting insulin at the time of food intake. Glycemic control was evaluated by CGM, and the Gastroparesis Cardinal Symptom Index (GCSI) was applied after meals. The CGM curve was different for MD + insulin and SD + insulin. There was a smaller increment of interstitial glucose with 2 h after MD + insulin, returning almost to the basal level 4 h later. Patients scored significantly lower GCSI after MD + insulin compared to the same index after they received SD + insulin. Moreover, there was a decrease in important clinical scores present in the index, like: "Not able to finish meal", "Loss of appetite" and "Stomach or belly feels larger”. This study showed that a modified diet can improve postprandial glycemic excursion and the perception and severity of gastroparesis symptoms.
- 19 September 2022
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 21 (2) , 1661-1667
Diet consistency modification improves postprandial glycemic and gastroparesis symptoms
Diabetic gastroparesis (DGP) is an autonomic neuropathy resulting from long-standing poorly controlled diabetes, and it is also linked to fluctuations in glycemic control due to variability on nutrient absorption. Considering the scarcity of information, the aim of this study was to identify the impact of modifications on diet consistency on post-prandial glucose variability using a continuous glucose monitoring (CGM) and its effect on the perception and severity of gastrointestinal symptoms. This proof-of-concept study was carried out in a cross-sectional cohort of six individuals with type 1 diabetes mellitus with confirmed diagnosis of DGP. Two types of diet were used to evaluate glycemic control and DGP symptoms, general consistency standard meal (SD) and modified consistency test diet (MD), associated with an application of rapid acting insulin at the time of food intake. Glycemic control was evaluated by CGM, and the Gastroparesis Cardinal Symptom Index (GCSI) was applied after meals. The CGM curve was different for MD + insulin and SD + insulin. There was a smaller increment of interstitial glucose with 2 h after MD + insulin, returning almost to the basal level 4 h later. Patients scored significantly lower GCSI after MD + insulin compared to the same index after they received SD + insulin. Moreover, there was a decrease in important clinical scores present in the index, like: "Not able to finish meal", "Loss of appetite" and "Stomach or belly feels larger”. This study showed that a modified diet can improve postprandial glycemic excursion and the perception and severity of gastroparesis symptoms.
- Open Access
- 5 July 2022
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 20, eAO8031
Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study
Objective To analyze interstitial glucose behavior during glucocorticoid use in non-diabetic patients receiving chemotherapy for hematologic malignancies. Methods Prospective pilot study carried out to assess interstitial glucose levels in 15 non-diabetic individuals with hematologic malignancies who received glucocorticoids in combination with chemotherapy. The FreeStyle Libre flash monitoring system (Abbott Diabetes Care) was used for up to 14 days to measure interstitial glucose. Results Median age and body mass index were 53 (42-61) years and 25 (23-28) kg/m2 respectively. Interstitial
- 5 July 2022
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 20, eAO8031
Open AccessEffects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study
Objective To analyze interstitial glucose behavior during glucocorticoid use in non-diabetic patients receiving chemotherapy for hematologic malignancies. Methods Prospective pilot study carried out to assess interstitial glucose levels in 15 non-diabetic individuals with hematologic malignancies who received glucocorticoids in combination with chemotherapy. The FreeStyle Libre flash monitoring system (Abbott Diabetes Care) was used for up to 14 days to measure interstitial glucose. Results Median age and body mass index were 53 (42-61) years and 25 (23-28) kg/m2 respectively. Interstitial
- Open Access
- 27 June 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (4) , 498-505
InsulinAPP application protocol for the inpatient management of type 2 diabetes on a hospitalist-managed ward: a retrospective study
Objective: We assessed metrics related to inpatient glycemic control using InsulinAPP, an application available for free in Brazil, on the hospitalist-managed ward of our hospital. Subjects and methods: We performed a retrospective study of patients with type 2 diabetes (T2D) admitted from November 2018 to October 2019. InsulinAPP recommends NPH and regular insulins three times a day, in bolus-correction or basal-bolus schemes. Parameters that included BG within range of 70-180 mg/dL, insulin treatment regimen and frequency of hypoglycemia were [...] ABSTRACT Objective: We assessed metrics related to inpatient glycemic control using InsulinAPP, an application available for free in Brazil, on the hospitalist-managed ward of our hospital. Subjects and methods: We performed a retrospective study of patients with type 2 diabetes (T2D) admitted from November 2018 to October 2019. InsulinAPP recommends NPH and regular insulins three times a day, in bolus-correction or basal-bolus schemes. Parameters that included BG within range of 70-180 mg/dL, insulin treatment regimen and frequency of hypoglycemia were
- 27 June 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (4) , 498-505
Open AccessInsulinAPP application protocol for the inpatient management of type 2 diabetes on a hospitalist-managed ward: a retrospective study
Objective: We assessed metrics related to inpatient glycemic control using InsulinAPP, an application available for free in Brazil, on the hospitalist-managed ward of our hospital. Subjects and methods: We performed a retrospective study of patients with type 2 diabetes (T2D) admitted from November 2018 to October 2019. InsulinAPP recommends NPH and regular insulins three times a day, in bolus-correction or basal-bolus schemes. Parameters that included BG within range of 70-180 mg/dL, insulin treatment regimen and frequency of hypoglycemia were [...] ABSTRACT Objective: We assessed metrics related to inpatient glycemic control using InsulinAPP, an application available for free in Brazil, on the hospitalist-managed ward of our hospital. Subjects and methods: We performed a retrospective study of patients with type 2 diabetes (T2D) admitted from November 2018 to October 2019. InsulinAPP recommends NPH and regular insulins three times a day, in bolus-correction or basal-bolus schemes. Parameters that included BG within range of 70-180 mg/dL, insulin treatment regimen and frequency of hypoglycemia were
- Open Access
- 30 July 2021
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 100 (3) , 246-253
Comparação entre o Teste de Senso de Posição Articular (TSPA), Teste do Diapasão (TD), Exame do Monofilamento de Semmes-Weinstein (EMSW) e Instrumento de Rastreio de Neuropatia de Michigan (QMNSI) na sensibilidade do diagnóstico da polineuropatia diabética
Objetivos: Comparar, em uma população com neuropatia diabética, a prevalência de alterações no teste da percepção da posição do hálux (teste do senso de posição articular - TSPA) com o teste do diapasão de 128 Hz (TD), exame do monofilamento de Semmes-Weinstein (EMSW) e os resultados do questionário elaborado para avaliação dos sintomas neuropáticos que faz parte do Instrumento de Rastreio de Neuropatia de Michigan (QMNSI). Casuística e métodos: Estudo retrospectivo de 35 pacientes ambulatoriais com polineuropatia diabética periférica confirmada por estudos de condução nervosa. Todos os pacientes foram submetidos à avaliaçao com TD, EMSW, QMNSI e TSPA. Neuropatia grave foi definida como polineuropatia periférica com ausência de resposta à estimulação elétrica por qualquer um dos nervos sensitivos ou motores. Resultados: A prevalência de anormalidade no TD (63%) e no QMNSI (69%) em pacientes com neuropatia diabética foi significativamente maior do que as alterações no TSPA (25,7%). A prevalência de anormalidade do TSPA e do TD foi maior em pacientes com anormalidades graves no estudo da condução nervosa. A avaliação simultânea com TD, EMSW e QMNSI foi a estratégia mais sensível para o diagnóstico de neuropatia diabética (sensibilidade, 89%). EMSW teve uma sensibilidade particularmente baixa (40%). As anormalidades do TSPA foram significativamente mais prevalentes nos pacientes com antecedente de ulcerações (p = 0,006). No entanto, a SPA não identificou um número maior de pacientes com ulcerações prévias quando comparado aos outros testes. Conclusões: O uso de apenas um teste clínico para triagem de neuropatia diabética, especialmente o TSPA e o EMSW, pode levar a uma sensibilidade consideravelmente menor quando comparado ao uso combinado de vários testes. Anormalidades do TSPA têm o potencial de indicar um quadro de neuropatia mais grave e com maior risco de ulcerações.
- 30 July 2021
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 100 (3) , 246-253
Open AccessComparação entre o Teste de Senso de Posição Articular (TSPA), Teste do Diapasão (TD), Exame do Monofilamento de Semmes-Weinstein (EMSW) e Instrumento de Rastreio de Neuropatia de Michigan (QMNSI) na sensibilidade do diagnóstico da polineuropatia diabética
Objetivos: Comparar, em uma população com neuropatia diabética, a prevalência de alterações no teste da percepção da posição do hálux (teste do senso de posição articular - TSPA) com o teste do diapasão de 128 Hz (TD), exame do monofilamento de Semmes-Weinstein (EMSW) e os resultados do questionário elaborado para avaliação dos sintomas neuropáticos que faz parte do Instrumento de Rastreio de Neuropatia de Michigan (QMNSI). Casuística e métodos: Estudo retrospectivo de 35 pacientes ambulatoriais com polineuropatia diabética periférica confirmada por estudos de condução nervosa. Todos os pacientes foram submetidos à avaliaçao com TD, EMSW, QMNSI e TSPA. Neuropatia grave foi definida como polineuropatia periférica com ausência de resposta à estimulação elétrica por qualquer um dos nervos sensitivos ou motores. Resultados: A prevalência de anormalidade no TD (63%) e no QMNSI (69%) em pacientes com neuropatia diabética foi significativamente maior do que as alterações no TSPA (25,7%). A prevalência de anormalidade do TSPA e do TD foi maior em pacientes com anormalidades graves no estudo da condução nervosa. A avaliação simultânea com TD, EMSW e QMNSI foi a estratégia mais sensível para o diagnóstico de neuropatia diabética (sensibilidade, 89%). EMSW teve uma sensibilidade particularmente baixa (40%). As anormalidades do TSPA foram significativamente mais prevalentes nos pacientes com antecedente de ulcerações (p = 0,006). No entanto, a SPA não identificou um número maior de pacientes com ulcerações prévias quando comparado aos outros testes. Conclusões: O uso de apenas um teste clínico para triagem de neuropatia diabética, especialmente o TSPA e o EMSW, pode levar a uma sensibilidade consideravelmente menor quando comparado ao uso combinado de vários testes. Anormalidades do TSPA têm o potencial de indicar um quadro de neuropatia mais grave e com maior risco de ulcerações.